Ask AI
ProCE Banner Activity

monarchE: Primary Analysis of OS With Adjuvant Abemaciclib Plus ET in Patients With High-Risk, Node-Positive, HR+/HER2- EBC

Conference Coverage
Slideset

The primary OS analysis of the phase III monarchE trial demonstrated a statistically significant improvement in OS with adjuvant abemaciclib plus ET vs ET alone in patients with high-risk, node-positive, HR+/HER2- EBC after a median follow-up of 6.3 years.

Released: October 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly